Sun Pharmaceutical Industries Limited has received approval from Brazil’s ANVISA to manufacture and market semaglutide injection. This treatment is for adults with inadequately controlled type 2 diabetes. The product will be launched in partnership with Hypera Pharma, a leading Brazilian company, and will be available in pre-filled pens. This move strengthens Sun Pharma’s diabetes portfolio in the LATAM region and expands access to crucial treatment options.
Brazil Approval for Diabetes Treatment
Sun Pharmaceutical Industries Limited announced on July 29, 2026, that it has received approval from the Brazilian Health Regulatory Agency, ANVISA. This approval grants Sun Pharma the authorization to manufacture and market semaglutide injection in Brazil. The medication is indicated for adults with type 2 diabetes mellitus who have inadequately controlled blood sugar levels, serving as an adjunct to diet and exercise.
Launch and Partnership Details
Sun Pharma plans to launch the semaglutide injection in Brazil within the next few days. The product will be introduced in partnership with Hypera Pharma, a prominent pharmaceutical company in Brazil. The injectable will be available in a convenient pre-filled, multi-dose pen format, offering two strengths: 2 mg/1.5 mL and 4 mg/3 mL, designed for flexible, once-weekly dosing.
Strategic Significance and Market Potential
Aalok Shanghvi, Chief Operating Officer of Sun Pharma, stated, “The approval of semaglutide in Brazil expands access to an evidence-based treatment option for people living with inadequately controlled type 2 diabetes. It reflects the strength of our development and manufacturing capabilities and our commitment to delivering high-quality medicines across global markets.” Digvijay Singh, Regional Head for Brazil & LATAM, added, “This approval marks an important step in strengthening our diabetes portfolio in Brazil.” The semaglutide injectable market in Brazil is estimated to be worth approximately USD 413 million (as of IQVIA, MAT June 2026).
About Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited is a leading global pharmaceutical company with a strong presence in Innovative Medicines, Generics, and Consumer Healthcare products. It is recognized as the largest pharmaceutical company in India and a leading generic company in the US and Global Emerging Markets. Sun Pharma’s portfolio includes innovative products in dermatology, ophthalmology, and oncodermatology. The company operates through vertically integrated facilities across five continents, delivering high-quality medicines to over 100 countries.
Source: BSE
